Advertisement

Breast Cancer Research and Treatment

, Volume 121, Issue 1, pp 177–184 | Cite as

Potentially functional polymorphisms in ESR1 and breast cancer risk: a meta-analysis

  • Ni Li
  • Jing Dong
  • Zhibin Hu
  • Hongbing Shen
  • Min DaiEmail author
Epidemiology

Abstract

Estrogen exposure is a central risk factor in the development of breast cancer. Estrogen receptor alpha (coded by ESR1) is the key mediator of estrogen response in mammary tissue. Genetic changes altering the expression of ESR1 is likely to affect breast cancer susceptibility. Since the identification of several potentially functional polymorphisms in ESR1 (rs2234693, rs9340799, rs1801132, rs3798577, rs2228480), molecular epidemiological studies were conducted in recent years to evaluate the association between polymorphisms and breast cancer risk in diverse populations. However, the results remain conflicting rather than conclusive. This current analysis on 10,300 breast cancer cases and 16,620 controls on rs2234693 showed a borderline significant decreased breast cancer risk for CC and CC/CT carriers (CC vs. TT: OR, 0.92, 95% CI, 0.86–0.99; CC/CT vs. TT: OR, 0.95, 95% CI, 0.89–1.00). Variant genotypes of the rs1801132 polymorphism were also associated with a decreased breast cancer risk in a dominant model in 5,649 cases and 6,856 controls (GG/GC vs. CC: OR, 0.92, 95% CI, 0.85–0.99). These results suggest that potentially functional ESR1 polymorphisms may play a low penetrance role in breast cancer susceptibility. SNPs rs9340799, rs3798577, rs2228480, and rs2077647 in ESR1 were not causative SNPs. SNPs rs2747648, rs1062577, and rs3020314 were recommended in further association studies and functional evaluations.

Keywords

ESR1 Polymorphism Function Breast cancer 

References

  1. 1.
    Key T, Appleby P, Barnes I, Reeves G (2002) Endogenous hormones and breast cancer collaborative group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–616PubMedGoogle Scholar
  2. 2.
    Khan SA, Rogers MA, Khurana KK, Meguid MM, Numann PJ (1998) Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90(1):37–42CrossRefPubMedGoogle Scholar
  3. 3.
    Zuppan P, Hall JM, Lee MK, Ponglikitmongkol M, King MC (1991) Possible linkage of the estrogen receptor gene to breast cancer in a family with late-onset disease. Am J Hum Genet 48(6):1065–1068PubMedGoogle Scholar
  4. 4.
    Zheng W, Long J, Gao YT, Li C, Zheng Y, Xiang YB, Wen W, Levy S, Deming SL, Haines JL, Gu K, Fair AM, Cai Q, Lu W, Shu XO (2009) Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet 2009 Mar; 41(3):324–328. Epub 2009 Feb 15Google Scholar
  5. 5.
    Cai Q, Shu XO, Jin F, Dai Q, Wen W, Cheng JR, Gao YT, Zheng W (2003) Genetic polymorphisms in the estrogen receptor alpha gene and risk of breast cancer: results from the Shanghai breast cancer study. Cancer Epidemiol Biomarkers Prev 12(9):853–859PubMedGoogle Scholar
  6. 6.
    Dunning AM, Healey CS, Baynes C, Maia AT, Scollen S, Vega A, Rodríguez R, Barbosa-Morais NL, Ponder BA; SEARCH, Low YL, Bingham S; EPIC, Haiman CA, Le Marchand L; MEC, Broeks A, Schmidt MK; ABCS, Hopper J, Southey M; ABCFS, Beckmann MW, Fasching PA; BBCC, Peto J, Johnson N; BBCS, Bojesen SE, Nordestgaard B; CGPS, Milne RL, Benitez J; CNIO-BCS, Hamann U, Ko Y; GENICA, Schmutzler RK, Burwinkel B; GC-HBOC, Schürmann P, Dörk T; HABCS, Heikkinen T, Nevanlinna H; HEBCS, Lindblom A, Margolin S; KARBAC, Mannermaa A, Kosma VM; KBCS, Chen X, Spurdle A; kConFab and the AOCS Management Group, Change-Claude J, Flesch-Janys D; MARIE, Couch FJ, Olson JE; for MCBCS, Severi G, Baglietto L; MCCS, Børresen-Dale AL, Kristensen V; NBCS, Hunter DJ, Hankinson SE; NHS, Devilee P, Vreeswijk M; ORIGO, Lissowska J, Brinton L; PBCS, Liu J, Hall P; SASBAC, Kang D, Yoo KY; SEBCS, Shen CY, Yu JC; TWBCS, Anton-Culver H, Ziogoas A; UCIBCS, Sigurdson A, Struewing J; USRTS, Easton DF, Garcia-Closas M, Humphreys MK, Morrison J, Pharoah PD, Pooley KA, Chenevix-Trench G, BCAC (2009) Association of ESR1 gene tagging SNPs with breast cancer risk. Hum Mol Genet 2009 Mar 15; 18(6):1131–1139. Epub 2009 Jan 6Google Scholar
  7. 7.
    González-Mancha R, Galán JJ, Crespo C, Pérez LI, González-Perez A, Morón FJ, Nogueira JAM, Real LM, Pascual MH, Ruiz A, Royo JL (2008) Analysis of the ERalpha germline PvuII marker in breast cancer risk. Med Sci Monit 14(3):CR136–CR143PubMedGoogle Scholar
  8. 8.
    González-Zuloeta Ladd AM, Vásquez AA, Rivadeneira F, Siemes C, Hofman A, Stricker BH, Pols HA, Uitterlinden AG, van Duijn CM (2008) Estrogen receptor alpha polymorphisms and postmenopausal breast cancer risk. Breast Cancer Res Treat 2008 Feb; 107(3):415–419. Epub 2007 Apr 24Google Scholar
  9. 9.
    Kjaergaard AD, Ellervik C, Tybjaerg-Hansen A, Axelsson CK, Grønholdt ML, Grande P, Jensen GB, Nordestgaard BG (2007) Estrogen receptor alpha polymorphism and risk of cardiovascular disease, cancer, and hip fracture: cross-sectional, cohort, and case–control studies and a meta-analysis. Circulation 115(7):861–871CrossRefPubMedGoogle Scholar
  10. 10.
    Onland-Moret NC, van Gils CH, Roest M, Grobbee DE, Peeters PH (2005) The estrogen receptor alpha gene and breast cancer risk (The Netherlands). Cancer Causes Control 16(10):1195–1202CrossRefPubMedGoogle Scholar
  11. 11.
    Shen Y, Li DK, Wu J, Zhang Z, Gao E (2006) Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case–control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 15(2):342–347CrossRefPubMedGoogle Scholar
  12. 12.
    Shin A, Kang D, Nishio H, Lee MJ, Park SK, Kim SU, Noh DY, Choe KJ, Ahn SH, Hirvonen A, Kim JH, Yoo KY (2003) Estrogen receptor alpha gene polymorphisms and breast cancer risk. Breast Cancer Res Treat 80(1):127–131CrossRefPubMedGoogle Scholar
  13. 13.
    Sonestedt E, Ivarsson MI, Harlid S, Ericson U, Gullberg B, Carlson J, Olsson H, Adlercreutz H, Wirfält E (2009) The protective association of high plasma enterolactone with breast cancer is reasonably robust in women with polymorphisms in the estrogen receptor alpha and beta genes. J Nutr 2009 May;139(5):993–1001. Epub 2009 Mar 25Google Scholar
  14. 14.
    Wang J, Higuchi R, Modugno F, Li J, Umblas N, Lee J, Lui LY, Ziv E, Tice JA, Cummings SR, Rhees B (2007) Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women. Breast Cancer Res Treat 2007 Dec;106(2):273–280. Epub 2007 Feb 1Google Scholar
  15. 15.
    Wedrén S, Lovmar L, Humphreys K, Magnusson C, Melhus H, Syvänen AC, Kindmark A, Landegren U, Fermér ML, Stiger F, Persson I, Baron J, Weiderpass E (2004) Oestrogen receptor alpha gene haplotype and postmenopausal breast cancer risk: a case control study. Breast Cancer Res 2004;6(4):R437–R449. Epub 2004 Jun 4Google Scholar
  16. 16.
    Comings DE, Gade-Andavolu R, Cone LA, Muhleman D, MacMurray JP (2003) A multigene test for the risk of sporadic breast carcinoma. Cancer 97(9):2160–2170CrossRefPubMedGoogle Scholar
  17. 17.
    Slattery ML, Curtin K, Giuliano AR, Sweeney C, Baumgartner R, Edwards S, Wolff RK, Baumgartner KB, Byers T (2007) Active and passive smoking, IL6, ESR1, and breast cancer risk. Breast Cancer Res Treat 2008 May;109(1):101–111. Epub 2007 Jun 27Google Scholar
  18. 18.
    Fernández LP, Milne RL, Barroso E, Cuadros M, Arias JI, Ruibal A, Benítez J, Ribas G (2006) Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case–control study. Int J Cancer 119(2):467–471CrossRefPubMedGoogle Scholar
  19. 19.
    Gallicchio L, Berndt SI, McSorley MA, Newschaffer CJ, Thuita LW, Argani P, Hoffman SC, Helzlsouer KJ (2006) Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. BMC Cancer 6:173CrossRefPubMedGoogle Scholar
  20. 20.
    Gold B, Kalush F, Bergeron J, Scott K, Mitra N, Wilson K, Ellis N, Huang H, Chen M, Lippert R, Halldorsson BV, Woodworth B, White T, Clark AG, Parl FF, Broder S, Dean M, Offit K (2004) Estrogen receptor genotypes and haplotypes associated with breast cancer risk. Cancer Res 64(24):8891–8900CrossRefPubMedGoogle Scholar
  21. 21.
    Siddig A, Mohamed AO, Awad S, Hassan AH, Zilahi E, Al-Haj M, Bernsen R, Adem A (2008) Estrogen receptor alpha gene polymorphism and breast cancer. Ann N Y Acad Sci 1138:95–107CrossRefPubMedGoogle Scholar
  22. 22.
    Weiderpass E, Persson I, Melhus H, Wedrén S, Kindmark A, Baron JA (2000) Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis 21(4):623–627CrossRefPubMedGoogle Scholar
  23. 23.
    Georgiou I, Syrrou M, Bouba I, Dalkalitsis N, Paschopoulos M, Navrozoglou I, Lolis D (1999) Association of estrogen receptor gene polymorphisms with endometriosis. Fertil Steril 72(1):164–166CrossRefPubMedGoogle Scholar
  24. 24.
    Weel AE, Uitterlinden AG, Westendorp IC, Burger H, Schuit SC, Hofman A, Helmerhorst TJ, van Leeuwen JP, Pols HA (1999) Estrogen receptor polymorphism predicts the onset of natural and surgical menopause. J Clin Endocrinol Metab 84(9):3146–3150CrossRefPubMedGoogle Scholar
  25. 25.
    Stavrou I, Zois C, Ioannidis JP, Tsatsoulis A (2002) Association of polymorphisms of the oestrogen receptor alpha gene with the age of menarche. Hum Reprod 17(4):1101–1105CrossRefPubMedGoogle Scholar
  26. 26.
    Gennari L, Becherini L, Masi L, Mansani R, Gonnelli S, Cepollaro C, Martini S, Montagnani A, Lentini G, Becorpi AM, Brandi ML (1998) Vitamin D and estrogen receptor allelic variants in Italian postmenopausal women: evidence of multiple gene contribution to bone mineral density. J Clin Endocrinol Metab 83(3):939–944CrossRefPubMedGoogle Scholar
  27. 27.
    Willing M, Sowers M, Aron D, Clark MK, Burns T, Bunten C, Crutchfield M, D’Agostino D, Jannausch M (1998) Bone mineral density and its change in white women: estrogen and vitamin D receptor genotypes and their interaction. J Bone Miner Res 13(4):695–705CrossRefPubMedGoogle Scholar
  28. 28.
    Herrington DM, Howard TD, Brosnihan KB, McDonnell DP, Li X, Hawkins GA, Reboussin DM, Xu J, Zheng SL, Meyers DA, Bleecker ER (2003) Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 2002 Apr 23;105(16):1879–1882. Erratum in: Circulation. 2003 Jul 29; 108(4):5001Google Scholar
  29. 29.
    Schuit SC, Oei HH, Witteman JC, Geurts van Kessel CH, van Meurs JB, Nijhuis RL, van Leeuwen JP, de Jong FH, Zillikens MC, Hofman A, Pols HA, Uitterlinden AG (2004) Estrogen receptor alpha gene polymorphisms and risk of myocardial infarction. JAMA 291(24):2969–2977CrossRefPubMedGoogle Scholar
  30. 30.
    Ioannidis JP, Ralston SH, Bennett ST, Brandi ML, Grinberg D, Karassa FB, Langdahl B, van Meurs JB, Mosekilde L, Scollen S, Albagha OM, Bustamante M, Carey AH, Dunning AM, Enjuanes A, van Leeuwen JP, Mavilia C, Masi L, McGuigan FE, Nogues X, Pols HA, Reid DM, Schuit SC, Sherlock RE, Uitterlinden AG, GENOMOS Study (2004) Differential genetic effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA 292(17):2105–2114CrossRefPubMedGoogle Scholar
  31. 31.
    Tchatchou S, Jung A, Hemminki K, Sutter C, Wappenschmidt B, Bugert P, Weber BH, Niederacher D, Arnold N, Varon-Mateeva R, Ditsch N, Meindl A, Schmutzler RK, Bartram CR, Burwinkel B (2009) A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. Carcinogenesis 2009 Jan; 30(1):59–64. Epub 2008 Nov 20Google Scholar
  32. 32.
    Modugno F, Zmuda JM, Potter D, Cai C, Ziv E, Cummings SR, Stone KL, Morin PA, Greene D, Cauley JA (2005) Estrogen metabolizing polymorphisms and breast cancer risk among older white women. Breast Cancer Res Treat 93(3):261–270CrossRefPubMedGoogle Scholar
  33. 33.
    Einarsdóttir K, Darabi H, Li Y, Low YL, Li YQ, Bonnard C, Sjölander A, Czene K, Wedrén S, Liu ET, Hall P, Humphreys K, Liu J (2008) ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res 2008; 10(1):R15. Epub 2008 Feb 14Google Scholar
  34. 34.
    Petitti DB (1994) Meta-analysis, decision analysis, and cost-effectiveness analysis. Oxford University Press, New YorkGoogle Scholar
  35. 35.
    Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127:820–826PubMedGoogle Scholar
  36. 36.
    Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedGoogle Scholar
  37. 37.
    Styrkarsdottir U, Halldorsson BV, Gretarsdottir S, Gudbjartsson DF, Walters GB, Ingvarsson T, Jonsdottir T, Saemundsdottir J, Center JR, Nguyen TV, Bagger Y, Gulcher JR, Eisman JA, Christiansen C, Sigurdsson G, Kong A, Thorsteinsdottir U, Stefansson K (2008) Multiple genetic loci for bone mineral density and fractures. N Engl J Med 2008 May 29; 358(22):2355–2365. Epub 2008 Apr 29Google Scholar
  38. 38.
    Herynk MH, Fuqua SA (2004) Estrogen receptor mutations in human disease. Endocr Rev 25(6):869–898CrossRefPubMedGoogle Scholar
  39. 39.
    Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM (2007) Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 67(20):9609–9612CrossRefPubMedGoogle Scholar
  40. 40.
    Fuqua SA, Fitzgerald SD, Chamness GC, Tandon AK, McDonnell DP, Nawaz Z, O’Malley BW, McGuire WL (1991) Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 51(1):105–109PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2009

Authors and Affiliations

  • Ni Li
    • 1
  • Jing Dong
    • 2
  • Zhibin Hu
    • 2
  • Hongbing Shen
    • 2
  • Min Dai
    • 1
    Email author
  1. 1.National Office of Cancer Prevention and Control, Cancer Hospital/InstituteChinese Academy of Medical SciencesBeijingChina
  2. 2.Department of Epidemiology and Biostatistics, Cancer CenterNanjing Medical UniversityNanjingChina

Personalised recommendations